-
2 months ago | 
precisionmedicineonline.com | Jessica Cohen |Alison Kanski |Catherine Shaffer |Ciara Curtin
NEW YORK – The life sciences sector is still reeling from the announcement last week that the US National Institutes of Health intends to limit indirect costs for research grants to15 percent. The policy has those in the precision medicine space particularly worried about the effect this may have on the bourgeoning field's ability to continue to develop advanced treatments like cell and gene therapies and maintain an expert workforce.
-
Jan 15, 2025 | 
precisionmedicineonline.com | Catherine Shaffer
NEW YORK – Olema Oncology shared recent data from ongoing trials of several investigational breast cancer therapies and provided a commercialization timeline for the estrogen receptor antagonist palazestrant at the 43rd annual JP Morgan Healthcare Conference on Tuesday.
-
Jan 10, 2025 | 
precisionmedicineonline.com | Catherine Shaffer
NEW YORK – Artificial intelligence tools based on natural language processing could ease the workload for clinical trial investigators by sifting through unstructured data in patient records and finding likely matches for clinical trials. Trials can have dozens of criteria that patients must meet to be eligible, including biomarkers, disease stage, disease subtype, age, general health status, and treatment history.
-
Dec 11, 2024 | 
precisionmedicineonline.com | Catherine Shaffer
SAN DIEGO – Patients with mantle cell lymphoma in their first remission who test negative for minimal residual disease (MRD) may be able to safely skip standard autologous hematopoietic stem cell transplant, according to an interim analysis of the ECOG-ACRIN and SWOG Phase III EA4151 clinical trial presented at the American Society of Hematology's annual meeting.
-
Dec 8, 2024 | 
precisionmedicineonline.com | Catherine Shaffer
Get the full story with Precision Medicine Online Premium Only $95 for the first 90 days
-
Nov 25, 2024 | 
precisionmedicineonline.com | Catherine Shaffer
NEW YORK – Results from a Phase III trial published in The New England Journal of Medicine last month will be practice-changing for doctors who treat patients with PIK3CA-mutated, hormone receptor (HR)-negative, HER2-negative locally advanced metastatic breast cancer. The data appear to put Roche's mutant PI3Kα inhibitor Itovebi (inavolisib) in a strongly competitive position against Novartis' Piqray (alpelisib), just as the former garnered marketing authorization in the US last month.
-
Nov 22, 2024 | 
precisionmedicineonline.com | Catherine Shaffer
NEW YORK – A new initiative within the Medical University of South Carolina Hollings Cancer Center will leverage artificial intelligence to identify and recommend individualized treatment strategies to cancer patients.
-
Nov 19, 2024 | 
precisionmedicineonline.com | Catherine Shaffer
NEW YORK – Lunit on Monday said that it has partnered with AstraZeneca to develop digital pathology tools that can predict the likelihood that a tumor harbors non-small cell lung cancer-driver mutations based on hematoxylin and eosin (H&E)-stained slide images. The firms aim to develop a rapid AI-powered screening tool for predicting actionable mutations, beginning with EGFR, from whole slide images of tissue samples.
-
Nov 7, 2024 | 
precisionmedicineonline.com | Catherine Shaffer
NEW YORK – Researchers at the University of California, San Francisco hope to establish new prostate-specific antigen (PSA) cut-off values for prostate cancer screening in transgender women after a study published in JAMA Network in June showed that using current thresholds, providers could miss cancer in some patients.
-
Oct 31, 2024 | 
360dx.com | Catherine Shaffer
NEW YORK – SkylineDx has scaled up efforts to drive adoption of its Merlin test in recent months after several new studies showcased its ability to predict which patients with cutaneous melanoma are at risk of metastasis and which can safely forgo sentinel lymph node biopsy surgery. The Merlin test, also called CP-GEP, combines clinicopathologic variables with gene-expression profiling via qPCR to stratify patients with cutaneous melanoma as high risk or low risk of nodal metastasis.
